ACBM ACRO BIOMEDICAL CO., LTD.
Services-Amusement & Recreation Services · OTC · SEC CIK 1622996 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-200.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-493.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets12,292.7%
Debt / equity—
Current ratio0.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $658,500 | $1.20M |
| Cost of revenue | — | — | $0 | $518,000 | $938,000 |
| Gross profit | — | — | $0 | $140,500 | $259,500 |
| R&D expense | — | $0 | $4.79M | $10.08M | $5.29M |
| SG&A expense | $154,024 | $37,958 | $3.52M | $5.93M | $2.67M |
| Operating income | -$154,024 | -$37,958 | -$8.80M | -$15.87M | -$7.69M |
| Interest expense | — | — | $3,206 | $1,706 | $893 |
| Pretax income | -$101,146 | -$42,297 | -$8.81M | -$15.87M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$101,146 | -$42,297 | -$8.81M | -$15.87M | -$7.70M |
| EPS (basic) | — | — | — | — | -0.14 |
| EPS (diluted) | 0.00 | 0.00 | -0.15 | -0.26 | — |
| Weighted avg. shares (diluted) | 60.04M | 60.04M | 60.04M | 60.04M | 53.84M |
| Balance sheet | |||||
| Cash & equivalents | $4,098 | $476 | $376 | $5,852 | $95,248 |
| Receivables | — | — | $0 | $638,500 | $598,000 |
| Inventory | — | — | — | — | $0 |
| Current assets | $14,098 | $5,076 | $1,626 | $657,537 | $706,415 |
| Total assets | $14,098 | $31,974 | $58,459 | $687,486 | $761,077 |
| Current liabilities | $401,062 | $326,946 | $288,575 | $201,116 | $91,651 |
| Total liabilities | $401,062 | $326,946 | $315,473 | $201,116 | $117,370 |
| Shareholders' equity | -$386,964 | -$294,972 | -$257,014 | $486,370 | $643,707 |
| Shares outstanding | 60.04M | 60.04M | 60.04M | 60.04M | 60.04M |
| Cash flow statement | |||||
| Operating cash flow | -$196,302 | -$36,692 | -$15,446 | -$147,481 | $299,335 |
| Financing cash flow | $199,924 | $36,792 | $9,970 | $58,085 | -$222,210 |
| Stock-based compensation | — | $0 | $8.06M | $15.71M | $7.65M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.